Gastric Motor Function Measurement in Dyspepsia and Normal Subjects

Inclusion criteria: Dyspeptic Subjects: Recurrent episodes of upper abdominal pain or discomfort including early satiety, fullness, bloating, or nausea for at least 3 months in the prior year. A baseline impaired satiety test (maximum tolerated volume 25% of normal or 1000cc). No evidence on esophagogastroduodenoscopy of erosions, peptic ulcer, pyloric obstruction, esophagitis or malignancy in the prior 3 years. All Subjects: No history suggestive of small bowel obstruction. Exclusion criteria No structural or metabolic diseases/conditions that affect the gastrointestinal system. Unable to stop medications 48 hours prior to the study that: Alter GI transit including laxatives, magnesium or aluminum-containing antacids, prokinetics, erythromycin, narcotics, anticholinergics, tricyclic antidepressants, SSRI and newer antidepressants. Analgesic drugs including opiates, NSAID, COX 2 inhibitors Systemic antifungal drugs Carbamazepine, glucocorticoids, phenobarbital, phenytoin, rifampin, but also grapefruit juice. Benzodiazepines NOTE: Low stable doses of thyroid replacement, estrogen replacement, low dose aspirin for cardioprotection and birth control pills or depot injections are permissible. Female subjects who are pregnant or breast feeding. Significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematological, neurological, psychiatric, or other disease that interfere with the objectives of the study. Subjects who have participated in another clinical study within the past 30 days. Previous gastric or intestinal surgery (except appendectomy , cholecystectomy or hysterectomy).